In Neurology Anneleen Berende, Roy Kessels, Bart-Jan Kullberg and colleagues showed that longer-term antibiotic treatment did not lead to better cognitive performance compared to a 2-week regimen in patients with Lyme disease-attributed persistent symptoms.
To investigate whether longer-term antibiotic treatment improves cognitive performance in patients with persistent symptoms attributed to Lyme borreliosis.
Data were collected during the Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) trial, a randomized, placebo-controlled study. Study participants passed performance-validity testing (measure for detecting suboptimal effort) and had persistent symptoms attributed to Lyme borreliosis. All patients received a 2-week open-label regimen of intravenous ceftriaxone before the 12-week blinded oral regimen (doxycycline, clarithromycin/hydroxychloroquine, or placebo). Cognitive performance was assessed at baseline and after 14, 26, and 40 weeks with neuropsychological tests covering the cognitive domains of episodic memory, attention/working memory, verbal fluency, speed of information processing, and executive function.
Baseline characteristics of patients enrolled (n = 239) were comparable in all treatment groups. After 14 weeks, performance on none of the cognitive domains differed significantly between the treatment arms (p = 0.49-0.82). At follow-up, no additional treatment effect (p = 0.35-0.98) or difference between groups (p = 0.37-0.93) was found at any time point. Patients performed significantly better in several cognitive domains at weeks 14, 26, and 40 compared to baseline, but this was not specific to a treatment group.
A 2-week treatment with ceftriaxone followed by a 12-week regimen of doxycycline or clarithromycin/hydroxychloroquine did not lead to better cognitive performance compared to a 2-week regimen of ceftriaxone in patients with Lyme disease-attributed persistent symptoms.
PublicationEffect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis.
Berende A, Ter Hofstede HJM, Vos FJ, Vogelaar ML, van Middendorp H, Evers AWM, Kessels RPC, Kullberg BJ.
Anneleen Berende and Bart-Jan Kullberg are members of theme Infectious diseases and global health.
Related news items
Frank Walboomers 25-years work anniversary at Radboudumc17 September 2020
Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.read more
Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes17 September 2020
Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.read more
Annette Schenck appointed professor of Translational Genetics17 September 2020
Annette Schenck has been appointed professor of Translational Genetics at the department of Neurodevelopmental disorders, with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.read more
Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients17 September 2020
Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.read more
Radboudumc does large-scale research on systemic sclerosis10 September 2020
In rare diseases, such as systemic sclerosis, it’s often difficult to conduct large-scale research. Rheumatologist Madelon Vonk has managed to follow enough patients with systemic sclerosis for years. The results of her research have been published in BMJ Annal of the Rheumatic Diseases.read more